Dr Reddys Laboratories (RDY) Selling, General & Administrative (2009 - 2026)
Dr Reddys Laboratories' Selling, General & Administrative was $304.42 million in the quarter ended Jun 30, 2026, up 1.6% from $299.68 million a year earlier and up 0.2% from the prior quarter.
Dr Reddys Laboratories (RDY) Selling, General & Administrative (2009 - 2026) Analysis & Trends
On a trailing twelve-month basis, Dr Reddys Laboratories' Selling, General & Administrative was $918.35 million through Jun 30, 2026, down 19.3% year-over-year; for the year ended Mar 31, 2026, it came in at $1.14 billion, up 3.5% from the prior year.
- Selling, General & Administrative has now increased for six consecutive years, with a five-year compound annual growth rate of 8.8% (years ended Mar 2021 to Mar 2026).
- In earlier years, Selling, General & Administrative was $1.1 billion in the year ended Mar 31, 2025 (+18.7%), $926 million in the year ended Mar 31, 2024 (+11.8%), $828 million in the year ended Mar 31, 2023 (+1.2%) and $818 million in the year ended Mar 31, 2022 (+9.5%).
- The figure for the quarter ended Jun 30, 2026 marks the highest quarterly Selling, General & Administrative since the quarter ended Jun 30, 2013.
- Compared with a year earlier, Selling, General & Administrative has increased for three straight quarters, with an average decline of 2.4% over the last eight quarters.
- The best year-over-year quarter for Selling, General & Administrative over five years was the quarter ended Sep 30, 2024 (growth of 20.8%); the worst was the quarter ended Sep 30, 2025 (a decline of 97.1%).
- Per Business Quant data, RDY's Selling, General & Administrative in the three quarters before the quarter ended Jun 30, 2026 was $303.69 million (quarter ended Mar 31, 2026), $302.27 million (quarter ended Dec 31, 2025) and $7.97 million (quarter ended Sep 30, 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,082.65 Bn | 1,051.23 Bn | 19.71 Bn | 3.43 Bn |
| 2 | Johnson & Johnson | 623.68 Bn | 542.21 Bn | 17.26 Bn | 6.43 Bn |
| 3 | AbbVie | 459.43 Bn | 432.59 Bn | 12.70 Bn | 3.63 Bn |
| 4 | Merck | 354.80 Bn | 309.23 Bn | 12.21 Bn | 2.90 Bn |
| 5 | Novartis Ag | 269.16 Bn | 225.03 Bn | 11.24 Bn | -3.24 Bn |
| 6 | Astrazeneca | 244.40 Bn | 217.97 Bn | 12.86 Bn | -5.65 Bn |
| 7 | Amgen | 220.17 Bn | 175.57 Bn | 7.24 Bn | 1.75 Bn |
| 8 | Gilead Sciences | 183.05 Bn | 157.16 Bn | 6.22 Bn | 1.92 Bn |
| 9 | Pfizer | 160.27 Bn | 107.22 Bn | 10.94 Bn | 3.41 Bn |
| 10 | Dr Reddys Laboratories | 10.22 Bn | 9.40 Bn | 396.53 Mn | 304.42 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 304.42 Mn |
| Mar 31, 2026 | 303.69 Mn |
| Dec 31, 2025 | 302.27 Mn |
| Sep 30, 2025 | 7.97 Mn |
| Jun 30, 2025 | 299.68 Mn |
| Mar 31, 2025 | 277.79 Mn |
| Dec 31, 2024 | 285.63 Mn |
| Sep 30, 2024 | 274.69 Mn |
| Jun 30, 2024 | 272.01 Mn |
| Mar 31, 2024 | 246.56 Mn |
| Dec 31, 2023 | 242.94 Mn |
| Sep 30, 2023 | 227.36 Mn |
| Jun 30, 2023 | 226.00 Mn |
| Mar 31, 2023 | 213.00 Mn |
| Dec 31, 2022 | 219.00 Mn |
| Sep 30, 2022 | 219.00 Mn |
| Jun 30, 2022 | 200.92 Mn |
| Mar 31, 2022 | 208.45 Mn |
| Dec 31, 2021 | 207.00 Mn |
| Sep 30, 2021 | 203.00 Mn |
Dr Reddys Laboratories Selling, General & Administrative API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=selling-general-and-administrative&ticker=RDY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "selling-general-and-administrative", "ticker": "RDY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=selling-general-and-administrative&ticker=RDY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();